Evaluating the Effects of Adjunctive Aripiprazole on Weight and Metabolic Outcomes in Females

Inclusion Criteria: * Females aged 18-65 years diagnosed with a mental health condition necessitating antipsychotic treatment. * Diagnosis of Schizophrenia or Schizoaffective Disorder * On stable doses of atypical antipsychotics, either Olanzapine, Clozapine, or Risperidone for at least 1 month * Willingness to comply with the study protocol. Exclusion Criteria: * Pregnancy or lactation. * Severe medical conditions impacting weight or metabolism. * Previous intolerance or contraindications to Aripiprazole. * Non-compliant with prescribed medications * Mental Retardation * Participant with an eating disorder * Participants with serious suicidal thoughts, or who pose a serious risk of harm to self or to others. * Diagnosis of Hyper or Hypothyroidism; Evidence of thyroid dysfunction as evidenced by serum thyroid function tests (i.e Thyroid Stimulating Hormone and -Free Thyroxine (fT4) levels \> 10 % above or below the limits of the normal range Use of any medication for weight loss within the past one month to the study entry * Clinically significant abnormalities in physical examinations, ECG or lab assessments